6FN.F KLARIA PHARMA HOLDING AB
- Market cap
- EUR 10.4M
- P/E
- -
- P/B
- 4.18x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6FN.F undervalued?
Graham numberThe Graham number of KLARIA PHARMA HOLDING AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KLARIA PHARMA HOLDING AB fundamental analysis
No fundamental analysis for KLARIA PHARMA HOLDING AB yet.
KLARIA PHARMA HOLDING AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KLARIA PHARMA HOLDING AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention o…
Full company profileKLARIA PHARMA HOLDING AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KLARIA PHARMA HOLDING AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 5.87M | 8.45M | 2.25M | 8.99M | 222K |
| Operating Income | -81.0M | -55.4M | -32.2M | -31.3M | -33.5M | -35.9M |
| EBITDA | - | -44.8M | -21.1M | -20.1M | -22.3M | -25.4M |
| Net Income | -53.5M | -63.8M | -35.8M | -47.8M | -47.1M | -43.1M |
| EPS | -0.94 | -0.79 | -0.33 | -0.32 | -0.19 | -0.18 |
| Balance Sheet | ||||||
| Total Assets | 118M | 120M | 72.9M | 57.3M | 32.5M | 37.5M |
| Total Liabilities | 48.9M | 44.2M | 31.8M | 54.0M | 44.6M | 71.1M |
| Shareholders' Equity | 69.4M | 76.1M | 41.1M | 3.30M | -12.0M | -33.6M |
| Cash & Short-term Investments | 25.5M | 16.8M | 1.25M | 598K | 342K | 8.47M |
| Cash Flow | ||||||
| Operating Cash Flow | -24.8M | -49.7M | -9.06M | -11.9M | -34.2M | -29.7M |
| Capital Expenditure | 0.00 | 42.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -24.8M | -49.8M | -9.06M | -11.9M | -34.2M | -29.7M |
| Ratios | ||||||
| ROE | -77.1% | -83.8% | -87.0% | -1,445.7% | - | - |
| ROA | -45.2% | -53.0% | -49.1% | -83.4% | -144.7% | -115.0% |
| Net Profit Margin | - | -1,086.8% | -423.3% | -2,124.1% | -523.8% | -19,407.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
KLARIA PHARMA HOLDING AB dividends
KLARIA PHARMA HOLDING AB has not paid dividends in the last 5 fiscal years.
Who owns KLARIA PHARMA HOLDING AB
- Insiders 16.77%
- Institutions 32.90%
- Public & others 50.34%
- Shares outstanding 246M
- Free float 241M
KLARIA PHARMA HOLDING AB company profile
- Company name
- KLARIA PHARMA HOLDING AB
- Ticker
- 6FN.F
- ISIN
- SE0007280326
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4
- Fiscal year end
- December
- Address
- Virdings Allé 2, Uppsala, Sweden, 754 50
- Phone
- 46 84 46 42 99
- Website
- klaria.com
About KLARIA PHARMA HOLDING AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.
KLARIA PHARMA HOLDING AB management
3- Dr. Scott BoyerCEO & Director · born 1962
- Mr. Hans RichterChief Financial Officer · born 1949
- Mr. Marc Willuhn Ph.D.Head of Chemistry, Manufacturing & Control · born 1969